About SPRAVATO®

What makes SPRAVATO® (esketamine) different?

Actor portrayal.

SPRAVATO® (esketamine) is the first and only NMDA receptor antagonist approved for 2 subtypes of MDD in adult patients1

SPRAVATO® hypothesized mechanism of action (MOA)

moa-desk

TRD=treatment-resistant depression in adults.

MDSI=depressive symptoms in adults with MDD with acute suicidal ideation or behavior.

UNMET NEED IN TRD

trd-depression

Even after multiple treatment steps, patients with TRD may continue to experience symptoms of MDD including2*:

 Depressed mood

 Loss of interest or pleasure

 Change in sleep, appetite, or weight

 Diminished concentration

 Feelings of worthlessness and guilt

 Psychomotor agitation or retardation

 Suicidal ideation

 Fatigue or loss of energy

In the STAR*D trial3

trd-1-in-3

 About one-third of patients with MDD did not respond to ≥2 oral ADs and may be considered to have TRD

 By the third line of oral therapy, remission rates dropped below 15%

trd-curve

SPRAVATO® clinical program overview

Studied in more than 1700 adult patients with treatment-resistant depression across all studies1

BASELINE PATIENT CHARACTERISTICS

trd-capsule

DID NOT RESPOND TO ≥2 and ≤5 ORAL ANTIDEPRESSANTS (ADs)

 Adults with major depressive disorder (MDD) who had not responded adequately in the current depressive episode to ≥2 and ≤5 different ADs of adequate dose and duration1,4

speedometer-desk

MODERATELY TO SEVERELY DEPRESSED

 Patients included those with moderate to severe depression, based on MADRS scores1

COMPARED TO PLACEBO NASAL SPRAY + ORAL AD1

COMPARED TO PLACEBO NASAL SPRAY + ORAL AD

MADRS=Montgomery-Åsberg Depression Rating Scale.

*DSM-5 criteria for major depressive disorder.

callout-background

Next: Efficacy in TRD and MDSI

Learn more

References:

1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.

2. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2010:1-152.

3. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.

4. Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study [published online May 21, 2019]. Am J Psychiatry. 2019;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172